Daewoong Pharma Gets India Nod
to Test Anti-parasite Drug for COVID-19
For treating COVID-19 patients in an early-stage human trial, South Korea’s Daewoong Pharmaceutical Co Ltd received Indian regulatory approval to test its anti-parasitic niclosamide drug to treat.
Daewoong, the South Korean drugmaker said in a statement that India’s Central Drugs Standard Control Organisation (CDSCO) approved the phase 1 trial which will kickstart this month and will involve around 30 healthy participants to test the safety of the drug.
The drug is being tested by Daewoong, in partnership with Mankind Pharma Ltd, New Delhi-based pharmaceutical company, which will continue the second and third phases of trials in India on patients tested positive with COVID-19 having mild and severe disease.
Daewoong said that for export permits in Europe and the United States, the trial results from India will be used. Nathan Kim, vice-president at Daewoong’s communications office said that the company is also waiting for a separate phase 1 trial approval from South Korea.
Daewoong had said that during its pre-clinical testing, the novel coronavirus from animals’ lungs was completely eliminated by its anti-viral drug.
Since the virus first emerged late last year in China, nearly 739,000 people globally have been killed by the virus so far, and drugmakers worldwide are scrambling to develop treatments for the illness caused by the COVID-19 causing virus, SARS-CoV-2. The United States is the worst affected country in the world followed by Brazil and India. In India, there are over 23,29,638 confirmed cases as of 12 August, with over 46,091 deaths reported across the country. Out of the confirmed cases in India, over 16,39,599 cases have recovered from the novel coronavirus infection. Maharashtra and TamilNadu are the worst affected states with 5,24,513 and 3,02,815 confirmed cases respectively. There are various vaccines likely to be successful in treating the virus, in progress, by various organizations worldwide.
Daewoong Pharma gets India nod